Genprex News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.02.22	Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes (Businesswire)
27.01.22	Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer (Businesswire)
10.01.22	Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer (Businesswire)
05.01.22	Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes (Businesswire)
04.01.22	Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer (Businesswire)
03.01.22	Genprex Receives FDA Fast Track Designation For REQORSA - Keytruda For NSCLC Treatment (RTTNews)
03.01.22	Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer (Businesswire)
23.06.21	Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review (Businesswire)
19.05.21	Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series (Businesswire)
10.05.21	Genprex to Participate in Upcoming May Investor Conferences (Businesswire)
06.05.21	Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer (Businesswire)
05.05.21	Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer (Businesswire)
04.05.21	Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer (Businesswire)
21.04.21	Genprex to Participate in CEO Roadshow Webinar Series (Businesswire)
20.04.21	Genprex to Receive Inaugural "License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes (Businesswire)
12.04.21	Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting (Businesswire)
05.04.21	Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean (Businesswire)
30.03.21	Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting (Businesswire)
24.03.21	Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29 (Businesswire)
01.03.21	Genprex to Participate in Upcoming March Investor Conferences (Businesswire)
09.02.21	Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants (Businesswire)
08.02.21	Genprex Announces Formation of Clinical Advisory Board (Businesswire)
04.02.21	Genprex Recognizes World Cancer Day (Businesswire)
01.02.21	Genprex Issues Shareholder Letter and Provides Corporate Update (Businesswire)
27.01.21	Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4 (Businesswire)
14.01.21	Genprex to Present at NobleCon17 on January 19 (Businesswire)
13.01.21	Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer (Businesswire)
24.12.20	Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants (Businesswire)
22.12.20	Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants (Businesswire)
22.12.20	Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer (Businesswire)
08.12.20	Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy (Businesswire)
03.12.20	Genprex to Present at the Benzinga Global Small Cap Conference on December 8 (Businesswire)
30.11.20	Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer (Businesswire)
24.11.20	Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1 (Businesswire)
11.11.20	Genprex to Participate in Panel at Life Sciences Summit on November 17 (Businesswire)
10.11.20	Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD (Businesswire)
30.10.20	Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer (Businesswire)
29.10.20	Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer (Businesswire)
26.10.20	Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing (Businesswire)
07.10.20	Genprex to Present at Zooming with LD Micro on October 14, 2020 (Businesswire)
06.10.20	Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa (Businesswire)
21.09.20	Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing (Businesswire)
02.09.20	Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs (Businesswire)
31.07.20	Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020 (Businesswire)
30.07.20	Genprex CEO Participates in a Second-Round Live Interview on the "Big Biz Show” (Businesswire)
23.07.20	Pre-market Movers In Healthcare Sector: ENTX, IMRN, CNTG, IMMP... (RTTNews)
21.07.20	National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex (Businesswire)
29.06.20	Genprex Added to Russell 3000® Index (Businesswire)
25.06.20	Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate (Businesswire)
24.06.20	Genprex CEO to Interview Live on "The Big Biz Show” (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	125.85	2.57 %	K V
Sika	232.30	1.84 %	K V
Swiss Re	132.20	1.58 %	K V
Logitech Intl	72.56	1.48 %	K V
ABB	51.02	1.47 %	K V
Nestle	76.60	0.16 %	K V
Sonova Hldg	300.80	0.00 %	K V
Novartis	93.14	-0.14 %	K V
Swisscom	507.00	-0.29 %	K V
Alcon	78.06	-0.41 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Genprex Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten